MERTK and breast carcinoma: BMS-777607 is currently undergoing phase II clinical trials for a number of different cancers, including breast cancer, and has activity against MET (IC50 3.9 nM), MERTK (IC50 14 nM) and NTRK1 (IC50 290 nM) [38].